参考文献/References:
[1] 中华人民共和国国家质量监督检验检疫总局.GB18871-2002电离辐射防护与辐射源安全基本标准[S].北京:中国标准出版社,2003.
[2] International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides[R]. ICRP Publication 94. Ann ICRP, 2004, 34(2):v-vi,1-79.
[3] European Commission. Radiation protection 97:radiation protection following iodine-131 therapy (exposures due to outpatients or discharged inpatients)[R]. Belgium:Office for Official Publications of the European Communities, 1998.
[4] Vetter RJ. Regulations for radioiodine therapy in the United States:current status and the process of change[J]. Thyroid, 1997,7(2):209-211.
[5] International Atomic Energy Agency. Nuclear medicine resources manual[R]. Vienna:International Atomic Energy Agency, 2006.
[6] 中华医学会内分泌学分会,中华医学会外科学分会,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床,2012,39(17):1249-1272.
[7] Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma[J]. J Clin Endocrinol Metab, 2002, 87(12):5817-5820.
[8] Jeong SY, Kim HW, Lee SW, et al. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer:direct comparison of pre-and postablation scintigraphies and their relation to xerostomia symptoms[J]. Thyroid, 2013, 23(5):609-616.
[9] Kolbert KS, Pentlow KS, Pearson JR, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software[J]. J Nucl Med, 2007, 48(1):143-149.
[10] Jentzen W, Schneider E, Freudenberg L, et al. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer[J]. Nucl Med Commun,2006,27(8):669-676.
[11] de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer[J]. J Nucl Med, 2004, 45(9):1549-1554.
[12] Lassmann M, H?nscheid H, Reiners C, et al. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH[J]. J Nucl Med, 2005, 46(5):900-901.
[13] 王建涛,赵卫威,刘斌,等.131I治疗对青少年分化型甲状腺癌患者外周血的影响[J].生物医学工程学杂志,2011,28(6):1185-1188.
[14] Pahlka RB, Sonnad JR. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients-a pharmacokinetic model[J].Health Phys, 2006, 91(3):227-237.
[15] Courbon F, Caselles O, Zerdoud S, et al. lodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease:clinical implications[J]. Q J Nucl Med Mol Imaging, 2006, 50(4):363-370.
[16] Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors[J]. Clin Endocrinol (Oxf), 2008, 69(3):479-490.
[17] Hyer S, Vini L, O’Connell M, et al. Testicular dose and fertility in men following I131 therapy for thyroid cancer[J].Clin Endocrinol (Oxf), 2002, 56(6):755-758.
[18] Garsi JP, Schlumberger M, Ricard M, et al. Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer[J]. Clin Endocrinol (Oxf), 2009, 71(6):880-883.
[19] Rosário PW, Barroso AL, Rezende LL, et al. Testicular function after radioiodine therapy in patients with thyroid cancer[J].Thyroid, 2006,16(7):667-670.
[20] Popova L, Hadjidekova V, Hadjieva T, et al. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma[J]. Hell J Nucl Med, 2005, 8(1):54-57.
[21] Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer:a systematic review and meta-analysis[J]. Thyroid, 2009,19(5):451-457.
[22] Samerdokiene V, Atkocius V, Ofomala R. Radiation exposure received by the medical radiation workers in Lithuania at the Institute of Oncology, Vilnius University, 2004-2011[J].Radiat Prot Dosimetry, 2013,157(1):152-157.
[23] Piwowarska-Bilska H, Supinska A, Listewnik MH, et al. Radiation doses of employees of a Nuclear Medicine Department after implementation of more rigorous radiation protection methods[J].Radiat Prot Dosimetry, 2013,157(1):142-145.
[24] Piwowarska-Bilska H, Birkenfeld B, Cwardys A, et al. Occupational exposure at the Department of Nuclear Medicine as a work environment:A 19-year follow-up[J]. Pol J Radiol, 2011, 76(2):18-21.
[25] Masood K, Ahmad M, Zafar J, et al. Assessment of occupational exposure among pakistani medical staff during 2007-2011[J].Australas Phys Eng Sci Med, 2012, 35(3):297-300.
[26] Kim CB, lung JW, Jeong KH, et al. Measurements and prediction of the ambient dose rate from patient receiving radioiodine administration after thyroid ablation[J].Radiat Prot Dosimetry, 2012, 151(1):158-161.
[27] Barrington SF, Kettle AG, O’Doherty MJ, et al. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid[J]. Eur J Nucl Med, 1996,23(2):123-130.
[28] Williams CE, Woodward AF. Management of the helpless patient after radioiodine ablation therapy-are we being too strict?[J]. Nucl Med Commun, 2005, 26(10):925-928.
[29] Cherry SR, Sorenson JA, Phelps ME. Physics in nuclear medicine[M]. 4th ed. Philadelphia:Saunders, 2012.
[30] Muir S, McLeod R, Dove R. Light-weight lead aprons-light on weight, protection or labelling accuracy?[J]. Australas Phys Eng Sci Med, 2005, 28(2):128-130.
[31] Fog LS,Collins P. Monte Carlo simulation of the dose to nuclear medicine staff wearing protective garments[J]. Australas Phys Eng Sci Med, 2008, 31(4):307-316.
[32] Young AM. Dose rates in nuclear medicine and the effectiveness of lead aprons:updating the department’s knowledge on old and new procedures[J]. Nucl Med Commun, 2013, 34(3):254-264.
[33] North DL. Uptake of 131I in households of thyroid cancer patients[J]. Health Phys, 2013, 104(4):434-436.
[34] Rémy H, Coulot J, Borget I, et al. Thyroid cancer patients treated with 131I:radiation dose to relatives after discharge from the hospital[J]. Thyroid, 2012, 22(1):59-63.
[35] Gabriel S, Farman-Ara B, Bourrelly M, et at. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer:poor compliance with radiation protection guidelines but low radiation exposure[J]. Nucl Med Commun, 2011, 32(9):829-833.
[36] de Carvalho JW, Sapienza M, Ono C, et al. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?[J]. Nucl Med Commun, 2009, 30(7):533-541.
[37] Willegaignon J, Sapienza M, Ono C, et al. Outpatient radioiodine therapy for thyroid cancer:a safe nuclear medicine procedure[J]. Clin Nucl Med, 2011,36(6):440-445.
[38] Sisson JC, Freitas J, McDougall IR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I:practice recommendations of the American Thyroid Association[J]. Thyroid,2011,21(4):335-346.
[39] Sapienza MT, Willegaignon J, Ono CR, et al. Radioiodine therapy of differentiated thyroid cancer:radiologic impact of out-patient treatment with 100 to ISO mCi Iodine-131 activities[J]. Arq Bras Endocrinol Metabol, 2009, 53(3):318-325.
[40] de Carvalho AB Jr, Hunt J, Silva AX, et al. Use of a voxel phantom as a source and a second voxel phantom as a target to calculate effective doses in individuals exposed to patients treated with 131I[J]. J Nucl Med Technol, 2009, 37(1):53-56.
[41] Asli IN, Baharfard N, Shafiei B, et al. Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma[J]. Radiat Prot Dosimetry, 2010,138(4):376-381.
[42] Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?[J].J Nucl Med, 2005, 46(2):261-266.
[43] Van Nostrand D, Atkins F, Bandaru VV, et al. Salivary gland protection with sialagogues:a case study[J]. Thyroid, 2009, 19(9):1005-1008.
[44] Kulkarni K, Van Nostrand D, Atkins F, et al. Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered?[J]. Nucl Med Commun, 2014,35(2):210-216.
[45] Fallahi B, Beiki D, Abedi SM, et al. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?[J].Nucl Med Commun, 2013, 34(8):777-786.
[46] Bhartiya US, loseph LJ, Raut YS, et aI. Effect of Ocimum sanctum, turmeric extract and vitamin E supplementation on the salivary gland and bone marrow of radioiodine exposed mice[J]. Indian J Exp Biol, 2010, 48(6):566-571.
[47] Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients:a prospective, randomized, single-blind, controlled trial[J]. J Nucl Med, 2010, 51(4):618-623.
[48] Mendoza A, Shaffer B, Karakla D, et al. Quality of life with well-differentiated thyroid cancer:treatment toxicities and their reduction[J]. Thyroid, 2004,14(2):133-140.
[49] Ma C, Xie J, Jiang Z, et al. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(9):1778-1785.
[50] Valdez IH, Wolff A, Atkinson JC, et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction[J]. Cancer, 1993,71(5):1848-1851.
[51] Almeida JP, Kowalski LP. Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy:a pilot study[J].Braz J Otorhinolaryngol, 2010, 76(5):659-662.
[52] Koca G, Cültekin SS, Han U, et al. The efficacy of montelukast as a protective agent against 131I-induced salivary gland damage in rats:scintigraphic and histopathological findings[J]. Nucl Med Commun, 2013,34(5):507-517.
[53] Hosseinimehr SJ. Potential utility of radioprotective agents in the practice of nuclear medicine[J]. Cancer Biother Radiopharm, 2009, 24(6):723-731.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[13]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[14]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[15]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[16]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[17]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[18]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[19]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
[20]董峰,周荫保.分化型甲状腺癌术后131I清甲效果的影响因素[J].国际放射医学核医学杂志,2010,34(1):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]
DONG Feng,ZHOU Yin-bao.Influencing factors of radioiodine ablation of posts-urgical thyroid remnants in differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):27.[doi:10.3760/cma.j.issn.1673-4114.2010.01.007]